Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Comment by CUR2004on Aug 26, 2011 3:35pm
361 Views
Post# 18984068

RE: Cur +

RE: Cur +This is not $5.1M/year...this is about $1M/year minimum for 5 years plus $5.7M 

in upfront payment for the acquisition of DiagnoCure’s U.S. laboratory. 

For the US$2.5M R&D agreement I don't know how they will receive it. 500k per year?

So I don't think they will be profitable for the next 2-3 quarter but with US sales of PCA3 and after the $59M cumulative sales Diagnocure will receive 16% of royalties and we should be profitable at this time.

I think cumulative sales of Gen-Probe were about $30M at last General Meeting in march.

Bullboard Posts